Alemtuzumab for Multiples Sclerosis: Who and When to treat?
Lancet 380:1795-1797, 1792, Springer, T. & Kappos, L., 2012
Mechanisms of Fingolimods Efficacy and Adverse Effects in Multiple Sclerosis
Ann Neurol 69:759-777, Cohen, J.A. & Chun, J., 2011
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
NEJM 359:1786-1801,1838, The CAMMS223 Trial Investigators, 2008
Immunization and MS
Neurol 59:1837-1843, Rutschmann,O.T.,et al, 2002
A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial of Influenza Immunizaation in MS
Neurol 48:312-314, Miller,A.E.,et al, 1997